The chondrosarcoma market is anticipated to increase during the forecast period (2026--2036), owing to improved diagnosis, treatment advancements, increased awareness, the launch of emerging therapies ...

Chondrosarcoma is a group of bone cancers that start in the cartilage. Cartilage is a connective tissue found in many parts of your body, such as in your joints where your bones meet. About 1 in ...

Interim data from expansion cohorts in patients with colorectal cancer and Ewing sarcoma demonstrate high response and disease control rates in difficult-to-treat, heavily pretreated patients ...

Chondrosarcoma is a type of bone cancer that forms in the cells of cartilage. Symptoms can vary but may include swelling and pain in the area of the tumor. Surgery is usually the first treatment for ...

Inhibrx Biosciences is vying for approval of its targeted therapy, ozekibart, in chondrosarcoma. This follows the positive outcome of the Phase II ChonDRAgon trial (NCT04950075), which found that ...

Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study Twenty-one patients (escalation, n = 12; ...

Osteosarcoma (OS), chondrosarcoma, and chordoma are characterized by multiple challenges to the investigator, clinician, and patient. One consequence of their rarity among sarcomas, as well as their ...

Mumbai: Dr Arsheed Hussain Hakeem, Senior Consultant – Surgical Oncology, Apollo Cancer Centre, Hyderabad speaking to Prabhat Prakash of ETHealthworld discussed the rarity of mesenchymal ...

Chondrosarcoma is a malignant tumour characterised by the generation of a cartilaginous matrix by neoplastic cells. When occurring in the craniofacial region, particularly within the temporomandibular ...

Please provide your email address to receive an email when new articles are posted on . The patient is a 57-year-old, right-handed, retired postal worker. He presented with a chief complaint of ...

--Company to Focus on Ongoing Development of Retaspimycin HCl and IPI-145; Results from Both Programs Expected in the Second Half of 2012 -- CAMBRIDGE, Mass., Jun 18, 2012 (BUSINESS WIRE) -- -- ...